Oncothyreon licenses broad spectrum Anti-Bcl-2 compound for oncology portfolio
This article was originally published in Scrip
Executive Summary
Oncothyreon, which has a portfolio of anticancer candidates, has obtained an exclusive licence from the Sanford-Burnham Medical Research Institute for the anticancer drug, sabutoclax, and related compounds. Sabutoclax is a pan-inhibitor of the Bcl-2 family of anti-apoptotic proteins currently in preclinical development.